Counterterrorism and Emerging Threats
FDA plays a critical role in protecting the United States from chemical, biological, radiological, nuclear, and emerging infectious disease threats. FDA ensures that medical countermeasures (MCMs)—including drugs, vaccines and diagnostic tests—to counter these threats are safe, effective, and secure.
Medical Countermeasures Initiative (MCMi)
MCM-related counterterrorism legislation
Federal legislation enacted to strengthen the nation’s preparedness for responding to public health emergencies involving chemical, biological, radiological, nuclear (CBRN) and emerging infectious disease threats.
Emergency Use Authorization (EUA)
The EUA authority allows FDA to help strengthen the nation’s public health protections against CBRN threats by facilitating the availability and use of MCMs needed during public health emergencies.
OCET Advanced Manufacturing
Advanced manufacturing technologies can improve drug quality, address shortages of medicines, and speed time-to-market.
Get the latest COVID-19 response updates from FDA.
More popular content
MCM-related and emergency preparedness and response topics, including Ebola, mpox, antimicrobial resistance, and more.
Office of Counterterrorism and Emerging Threats
OCET provides leadership, coordination, and oversight for FDA’s national and global health security, counterterrorism, and emerging threats portfolios.
Assistant Commissioner for Counterterrorism Policy, and Director, OCET